Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer
- Qualigen Therapeutics announces a poster presentation on their Pan-RAS platform at the AACR Special Conference
- The Pan-RAS approach may potentially overcome KRAS G12C resistance in emerging therapies
- Qualigen's RAS inhibitors suppress RAS signaling pathways in Luminal B breast cancer models
- Pan-RAS compounds are active against in vivo xenograft breast tumors and can be orally available
- None.
Poster Includes Preclinical Data on Pan-RAS Compounds Demonstrating Inhibition in Breast Cancer Models
CARLSBAD, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces a poster presentation on the Company’s Pan-RAS platform at the American Association for Cancer Research (AACR) Special Conference in Breast Cancer Research, held October 19th to 22nd at the Westin San Diego Bayview.
“The RAS pathway continues to be an area of immense interest within the scientific community and biopharmaceutical industry. Due to the prevalence and severity of RAS-driven tumors, there is a high unmet need to discover and develop more broadly acting RAS-targeted compounds. We believe a pan-RAS approach may potentially overcome KRAS G12C resistance that affects depth and duration of responses of emerging therapies,” commented Michael Poirier, Qualigen’s Chairman and CEO. “We are grateful for our partnership with Dr. Geoff Clark and his team at the University of Louisville, who have demonstrated the therapeutic potential of our approach to RAS.”
RAS is seldom mutated in breast cancer, but it is often hyperactivated by upregulation of positive regulator activity (such as Her-2) or down-regulation of negative regulator activity (such as NF1 or DAB2IP). These effects are particularly common in Luminal B breast cancer. As a result, we have developed a series of novel direct Pan-RAS inhibitors that exhibit a distinct binding mechanism to other currently described RAS inhibitors.
Poster highlights included:
Our RAS inhibitors suppressed the interaction of RAS with its downstream mitogenic effectors and suppressed RAS signaling pathways (MAPK and RAL pathways) in Luminal B breast cell model systems.
Our Pan-RAS compounds inhibited 3D growth at doses that have little effect on normal 2D growth and are active against in vivo xenograft breast tumors and can be orally available.
| Abstract #: | B020 |
| Title: | “Pan-RAS Inhibitors to Treat Luminal B Breast Cancer” |
| Author/s: | Geoff Clark, Ph.D., et. al. |
| Presentation Date: | October 21, 2023 5:00 to 7:00pm PT |
| Location | Westin San Diego Bayview |
RAS is the most common cancer oncogene. Activating mutations in one of the three human RAS gene isoforms (KRAS, HRAS, or NRAS) are present in about one-fourth of all cancers. For example, mutant KRAS is found in
About Pan-RAS
Qualigen Therapeutics is collaborating with Dr. Geoff Clark and Dr. Joe Burlison at the University of Louisville, Kentucky to develop a series of potentially highly potent compounds to take forward into preclinical development. Lead compounds are believed to suppress or block the interaction of endogenous RAS with c-RAF, and thereby influence the KRAS, HRAS, and NRAS effector pathways. RAS acts as a “hub” that activates multiple effector pathways, hence blocking any single pathway may be ineffective for many RAS-driven tumor types, including pancreatic, lung, and colorectal cancers. This approach could potentially enable a differentiated, pan-RAS strategy for inhibiting the MAPK, PI3K, and RAL pathways implicated in cancer cell proliferation, survival, and differentiation.
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. Our investigational QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation. The investigational compounds within Qualigen’s family of Pan-RAS oncogene protein-protein interaction inhibitor small molecules are believed to block the binding of mutated RAS proteins to their effector proteins, thereby leaving the mutated RAS unable to cause further harm. In theory, such mechanism of action may be effective in the treatment of about one quarter of all cancers, including certain forms of pancreatic, colorectal, and lung cancers.
Forward-Looking Statements
This news release contains forward-looking statements by Qualigen that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. These statements include those related to the Company's prospects and strategy for development of its therapeutic drug candidates, including the anticipated timeline for initiating the Company’s Phase 1 clinical trial and enrolling and dosing of patients and the identification of a late in vivo candidate. Actual events or results may differ from the Company's expectations. There can be no assurance that the Company will be able to successfully develop any drugs (including QN-302, Pan-RAS and QN-247); that preclinical development of the Company's drugs (including Pan-RAS and QN-247) will be completed on any projected timeline or will be successful; that any clinical trials will be approved to begin by or will proceed as contemplated by any projected timeline, or at all; that any future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that preclinical study results the Company observed in animals will be borne out in human patients; that any drugs will receive required regulatory approvals (or Fast Track designation or Orphan Drug status) or that they will be commercially successful; that patents will issue on the Company's owned and in-licensed patent applications; that such patents, if any, and the Company's currently owned and in-licensed patents would prevent competition; or that the Company will be able to procure or earn sufficient working capital to complete the development, testing and launch of the Company's prospective therapeutic products (including QN-302, Pan-RAS and QN-247). The Company's stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fail to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting the Company's business can be found in the Company's prior filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K, all of which are available at www.sec.gov.
The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
For more information about Qualigen Therapeutics, Inc., please visit www.qlgntx.com.
Contact:
Investor Relations
ir@qlgntx.com
Source: Qualigen Therapeutics, Inc.
FAQ
What did Qualigen Therapeutics announce at the AACR Special Conference?
What potential does the Pan-RAS approach have?
What did Qualigen's RAS inhibitors demonstrate in Luminal B breast cancer models?
Are Pan-RAS compounds effective against breast tumors?
How can Pan-RAS compounds be administered?
